Aufgereinigtes Polypeptid, dessen Aminosäuresequenz im Wesentlichen identisch ist mit der Aminosäuresequenz von SEQ ID NO:1 und SEQ ID NO:3, wobei das Polypeptid low density lipoproteins (LDL) und/oder oxidiertes LDL (ox-LDL), insbesondere LDL-Cholesterin und/oder oxidiertes LDL-Cholesterin (oxLDL-Cholesterin), bindet. Die Erfindung beinhaltet die Verwendung des Polypeptides in Kombination mit üblichen Hilfs- und/oder Trägerstoffen zur Herstellung eines Arzneimittels mit fettsenkender Wirkung sowie von Medikamenten zur Behandlung von Nierenerkrankungen.Purified polypeptides (I) are new. They have an amino acid (aa) sequence practically identical with sequences (1； 96 aa) and/or (3； 110 aa), reproduced, and bind to low density lipoprotein (LDL), especially LDL-cholesterol, and/or their oxidized forms. Independent claims are also included for the following: (1) purified polypeptides that include sequences (1) and/or (3)； (2) complementarity determining regions (CDR), or their functional fragments, of (1) and/or (3)； and (3) method for generating antibodies (Ab) by the hybridoma technique in which hybridomas are prepared from the heteromyeloma cell line HAB-1, or its subclones, and B lymphocytes from human spleen, lymph nodes or blood. ACTIVITY : Antilipemic； Nephrotropic； Antiarteriosclerotic； Cardiant. Purified SAM-6.10 antibody (containing (1) and (3) as its variable regions) was injected (1 mg) intraperitoneally into mice, then the LDL content in the serum determined. The contents were 14 and 12 mg/dl after 24 and 48 hours, respectively； contrast 18 and 17 for an animal injected with 1 mg of an isotype control antibody. MECHANISM OF ACTION : Binding to (oxidized) low density lipoprotein, so functioning in a manner analogous to the known scavenger pathway.
